New data presented at the AACR meeting this week in Atlanta provided promising results for a targeted therapy for patients with pancreatic cancer. Results from an ongoing phase II clinical trial of the PARP inhibitor rucaparib provided encouraging results for pancreatic cancer patients with
with advanced BRCA-or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy.